证券代码：920575 证券简称：康乐卫士 公告编号：2026-008 (一)业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 (二)业绩预告情况 √年度净利润为负值 单位：万元 北京康乐卫士生物技术股份有限公司 2025 年年度业绩预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、本期业绩预告情况 | 项目 | | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | --- | | 归属于上市 | 公司 | -33,967.20～-27,791.35 | -35,660.62 | 4.75%～22.07% | | 股东的净利润 | | | | | 二、本期业绩重大变化的主要原因 公司自成立以来持续进行疫苗产品研发，截至 2025 年 12 月 3 ...

证券之星消息，1月28日生物制品板块较上一交易日下跌1.98%，百普赛斯领跌。当日上证指数报收于 4151.24，上涨0.27%。深证成指报收于14342.9，上涨0.09%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301080 | 百普赛斯 | 58.18 | -10.57% | 5.74万 | 3.42亿 | | 920575 | 康乐卫士 | 10.97 | -6.16% | 12.07万 | 1.36亿 | | 688137 | 近岸蛋白 | 46.58 | -5.90% | 2.88万 | 1.36亿 | | 6168889 | 欧林生物 | 24.88 | -5.51% | 7.81万 | 1.97亿 | | 000518 | *ST四环 | 2.63 | -5.05% | 19.04万 | 5010.80万 | | 300318 | 博晖创新 | 7.27 | -4.97% | 64.60万 | 4.78亿 | | 301207 | 华兰婷曲 ...

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with notable increases such as Kanglaweishi up over 20% and several others reaching the daily limit of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has prompted a response from local authorities, with nearly a hundred individuals under home quarantine due to the high mortality rate of up to 75% and the absence of a vaccine [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal starting January 26 to prevent the virus from entering Thailand [1] Group 2 - Historical context indicates that Nipah virus outbreaks have previously occurred in Malaysia, Singapore, India, Bangladesh, and the Philippines, resulting in significant fatalities and the culling of millions of pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission rate through contaminated food or direct human-to-human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days, and there are currently no specific vaccines or effective treatments available [2] Group 3 - The stock performance of various biopharmaceutical companies shows substantial year-to-date gains, with Kanglaweishi at 45.10%, Maike Biological at 26.90%, and Kaipu Biological at 34.76% [3] - Other companies such as Zhijiang Biological and Jindike also reported significant increases, with year-to-date growth rates of 26.67% and 18.44% respectively [3] - The overall market trend indicates a strong investor interest in biopharmaceutical stocks amid the health crisis related to the Nipah virus outbreak [1][3]

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with Kang Le Wei Shi increasing by over 20% and several other companies reaching their daily limit up of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has led to a human-to-human transmission risk, with a mortality rate as high as 75% and no vaccine currently available [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal, India, starting January 26, to prevent the virus from entering Thailand [1] Group 2 - Historical context shows that Nipah virus outbreaks previously occurred in Malaysia and Singapore from 1998 to 1999, resulting in over a hundred deaths and the culling of a million pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission potential through contaminated food or direct human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days before symptoms appear [2] Group 3 - Notable stock performances include: - Kang Le Wei Shi: 20.48% increase, market cap of 3.371 billion - Mai Ke Biological: 20.03% increase, market cap of 8.586 billion - Kai Pu Biological: 20.03% increase, market cap of 4.687 billion - Zhi Jiang Biological: 20.01% increase, market cap of 4.910 billion - Jin Di Ke: 13.72% increase, market cap of 2.952 billion [3] - Other companies with significant increases include Zhi Fei Biological (13.31%), Kang Xi Nuo (12.77%), and Bai Pu Sai Si (12.01%) [3]

Core Viewpoint - The company, Kang Le Wei Shi, has announced the suspension of clinical trials for its three-valent and nine-valent HPV vaccines due to overdue funding and financial pressures, which have been a recurring issue for the company [1][4]. Group 1: Clinical Trial Suspension - The clinical trials for the three-valent and nine-valent HPV vaccines have been paused by the Shanxi and Jiangsu Provincial Centers for Disease Control due to overdue clinical trial funding [1]. - The three-valent HPV vaccine's phase III clinical trial is expected to reach its pathological endpoint (CIN2+) by August 2024, and the suspension is not anticipated to significantly impact the accumulated qualified cases or the upcoming Biologics License Application (BLA) [2]. - The nine-valent HPV vaccine (female indication) has completed the primary endpoint case collection but may face challenges in secondary endpoint case collection and BLA submission if the trial does not resume soon [3]. Group 2: Financial Challenges - The company has faced significant financial pressure, previously announcing issues with repaying bank loans and having multiple bank accounts frozen due to liquidity problems [4]. - As of December 31, 2024, the company's cash balance was 77.77 million yuan, with total current assets of 117 million yuan, and by September 30, 2025, cash had decreased to 6.32 million yuan, a 91.88% year-on-year decline [5]. - The company has yet to commercialize its core products, with revenue primarily from research testing reagents, reporting revenues of 885,600 yuan in 2024 and a net loss of 357 million yuan [5].

Core Insights - The HPV vaccine sales slump is leading to significant financial losses for companies in the sector, particularly for Zhifei Biological, which anticipates a net loss of 10.698 billion to 13.726 billion yuan in 2025 [1][2] - The HPV vaccine market is experiencing a shift from a blue ocean to a red ocean, with increased competition from domestic vaccine manufacturers reducing the first-mover advantage previously held by Zhifei Biological [2] Company-Specific Insights - Zhifei Biological's major products, the four-valent and nine-valent HPV vaccines, have seen sales underperform due to declining public willingness to get vaccinated and increased vaccine hesitancy [2] - The company has reported its first loss since it began selling HPV vaccines in 2017, following years of profitability that peaked at over 10 billion yuan in 2021 [1] - The stock price of Zhifei Biological has significantly decreased from a peak of 152.06 yuan per share in June 2021 to 17.56 yuan per share currently [5] Industry Insights - The number of HPV vaccines available in China has reached seven, with price competition intensifying as public procurement prices for some vaccines have dropped to 27.5 yuan per dose [2] - Companies involved in HPV vaccine research, such as Kangla Weishi, are facing funding challenges that have led to the suspension of clinical trials for their HPV vaccines [3][4] - The overall market for HPV vaccines is experiencing a slowdown in growth due to factors such as reduced demand for vaccinations and increased competition, making it harder for companies to attract investment [5]

Core Viewpoint - The company, 康乐卫士, has announced the suspension of its Phase III clinical trials for both the trivalent and nine-valent HPV vaccines due to overdue funding and insufficient on-site research funds, as communicated by health authorities in Shanxi and Jiangsu provinces [1][2] Group 1: Clinical Trial Suspension - The trivalent HPV vaccine (16/18/58 types) and the nine-valent HPV vaccine (6/11/16/18/31/33/45/52/58 types) clinical trials have been suspended due to overdue clinical trial funding [1] - The suspension is primarily due to the inability to continue gynecological visits necessary for the trials [1] Group 2: Impact on Clinical Trials - The trivalent HPV vaccine has already met the endpoint case collection requirements for its clinical protocol and is expected to have its market approval application accepted by April 2025, indicating that the suspension will not significantly impact this project [1] - The nine-valent HPV vaccine has completed the collection of cases for its primary endpoint and is currently in the process of accumulating secondary endpoint cases, but prolonged suspension may adversely affect this aspect [2] Group 3: Funding and Future Actions - The company is actively seeking funding through various channels to resolve overdue payments and resume normal clinical trial operations [2] - There is a risk that stakeholders may terminate the project if the company fails to make timely payments for overdue funding [2]

证券代码：920575 证券简称：康乐卫士 公告编号：2026-007 北京康乐卫士生物技术股份有限公司 关于三价和九价 HPV 疫苗临床试验暂停的公告 三、风险提示 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、临床试验暂停的原因 近日，北京康乐卫士生物技术股份有限公司（以下简称"公司"）收到山西 省疾病预防控制中心发送的《关于暂停重组三价和重组九价人乳头瘤病毒疫苗Ⅲ 期临床试验的函》及江苏省疾病预防控制中心发送的《关于暂停重组九价人乳头 瘤病毒疫苗Ⅲ期临床试验的函》。根据函件内容，由于公司临床试验经费支付逾 期，现场研究经费短缺，无法继续开展后续妇科访视工作。因此，山西省疾病预 防控制中心暂停公司重组三价人乳头瘤病毒（16/18/58 型）疫苗（大肠杆菌）（以 下简称"三价 HPV 疫苗"）和重组九价人乳头瘤病毒（6/11/16/18/31/33/45/52/58 型）疫苗（大肠埃希菌）（以下简称"九价 HPV 疫苗"）（女性适应症）Ⅲ期临床 试验，江苏省疾病预防控制中心暂停公司九价 HPV ...

证券代码：920575 证券简称：康乐卫士 公告编号：2026-006 北京康乐卫士生物技术股份有限公司 解除股权质押的公告 2026 年 1 月 15 日 （一） 本次解除股权质押基本情况 公司接到控股股东天狼星控股集团有限公司的通知，控股股东天狼星控股集 团有限公司本次解除股份质押 6,000,000 股，占其所持股份 9.93%，占公司总股 本 2.14%。本次解质的股份中，6,000,000 股为有限售条件股份，0 股为无限售 条件股份，解质的股份已在中国结算办理相关手续，解除日期为 2026 年 1 月 13 日。上述股份于 2024 年 12 月 31 日被质押，质押权人为中信银行股份有限公司 昆明分行。 （二） 剩余被质押股权的情况 截至公告披露日，公司控股股东天狼星控股集团有限公司剩余被质押的股份 为 27,455,697 股，占其所持股份的 45.43%，占公司总股本的 9.77%。剩余被质 押股份中，27,455,697 股为有限售条件股份，0 股为无限售条件股份。 二、 备查文件目录 中国证券登记结算有限责任公司出具的《解除证券质押登记通知》 北京康乐卫士生物技术股份有限公司 董事会 本 ...

证券之星消息，1月15日生物制品板块较上一交易日下跌0.82%，康乐卫士领跌。当日上证指数报收于 4112.6，下跌0.33%。深证成指报收于14306.73，上涨0.41%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688488 | 文迪药业 | 20.98 | 5.80% | 21.79万 | | 4.54亿 | | 603087 | 日李药业 | 72.55 | 4.69% | 16.82万 | | 12.25亿 | | 688293 | 奥浦迈 | 58.73 | 3.78% | 2.06万 | | 1.20亿 | | 688278 | 特宝生物 | 76.18 | 1.65% | 3.44万 | | 2.62亿 | | 688331 | 荣昌生物 | 104.90 | 1.51% | 10.51万 | | 11.06亿 | | 000534 | 万泽股份 | 22.18 | 1.32% | 12.60万 | | 2.78亿 | | 3 ...